Alterity Therapeutics (ATHE) to Release Quarterly Earnings on Friday

Alterity Therapeutics (NASDAQ:ATHE) will likely be issuing its Q4 2026 TU results before the market opens on Friday, August 28th. Analysts expect Alterity Therapeutics to announce earnings of ($0.1218) per share and revenue of $2.3210 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2026 TU earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 PM ET.

Alterity Therapeutics Price Performance

Shares of ATHE stock opened at $4.78 on Thursday. Alterity Therapeutics has a 1 year low of $2.66 and a 1 year high of $5.89. The company’s fifty day simple moving average is $4.86 and its two-hundred day simple moving average is $4.24.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC bought a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics at the end of the most recent quarter. 2.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ATHE. Craig Hallum set a $2.00 price target on Alterity Therapeutics in a research report on Tuesday, August 11th. JonesTrading began coverage on Alterity Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $16.00 price target for the company. LADENBURG THALM/SH SH started coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 target price on the stock. UBS Group set a $12.00 price target on Alterity Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.